Xvivo Perfusion AB (Xvivo Perfusion AB) 3-Year Book Growth Rate : 20.70% (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Xvivo Perfusion AB 3-Year Book Growth Rate?

Xvivo Perfusion AB's Book Value per Share for the quarter that ended in Mar. 2024 was $6.11.

During the past 12 months, Xvivo Perfusion AB's average Book Value per Share Growth Rate was 31.10% per year. During the past 3 years, the average Book Value per Share Growth Rate was 20.70% per year. During the past 5 years, the average Book Value per Share Growth Rate was 26.10% per year. During the past 10 years, the average Book Value per Share Growth Rate was 27.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

During the past 12 years, the highest 3-Year average Book Value per Share Growth Rate of Xvivo Perfusion AB was 39.50% per year. The lowest was 17.40% per year. And the median was 28.60% per year.

Competitive Comparison of Xvivo Perfusion AB's 3-Year Book Growth Rate

For the Medical Devices subindustry, Xvivo Perfusion AB's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Xvivo Perfusion AB's 3-Year Book Growth Rate Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Xvivo Perfusion AB's 3-Year Book Growth Rate distribution charts can be found below:

* The bar in red indicates where Xvivo Perfusion AB's 3-Year Book Growth Rate falls into.

Xvivo Perfusion AB 3-Year Book Growth Rate Calculation

This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

Xvivo Perfusion AB (OTCPK:XVIPF) 3-Year Book Growth Rate Explanation

Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.

Xvivo Perfusion AB 3-Year Book Growth Rate Related Terms

Thank you for viewing the detailed overview of Xvivo Perfusion AB's 3-Year Book Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Xvivo Perfusion AB (Xvivo Perfusion AB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Xvivo Perfusion AB (OTCPK:XVIPF) » Definitions » 3-Year Book Growth Rate

Comparable Companies

Traded in Other Exchanges

XVIVO:Sweden 3XV:Germany

Address

Massans gata 10, P.O. Box 53015, Gothenburg, SWE, SE-400 14

Website

https://www.xvivoperfusion.com

Xvivo Perfusion AB is a medical technology company dedicated to extending the life of all major organs so transplant teams around the world can save more lives. Its solutions allow clinicians and researchers to push the boundaries of transplantation medicine. It operates in three segments namely, Thoracic: Sales of lung and heart transplant products, Abdominal: Sales of liver and kidney transplant products. Services: Revenue from sales of services in organ recovery (carried out by subsidiary STAR Teams Inc.). The majority of revenue is derived from the Thoracic segment. Geographically, the majority is from the United States.